CD5 CAR‑T treatment for relapsed or hard‑to‑treat T‑cell lymphoma
Project 2: CAR-T cell therapy for T cell lymphoma
['FUNDING_OTHER'] · BAYLOR COLLEGE OF MEDICINE · NIH-11178348
This project is trying CD5‑targeted CAR‑T cell therapy, including faster off‑the‑shelf products, to help people with relapsed or refractory T‑cell lymphoma get better responses.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BAYLOR COLLEGE OF MEDICINE (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11178348 on ClinicalTrials.gov |
What this research studies
If I have relapsed or refractory T‑cell lymphoma, this work builds on earlier patient treatments that produced meaningful responses and aims to make those therapies stronger and easier to get. The team will use drugs during cell manufacturing to prevent harmful overactivation and preserve healthier CAR‑T cells. They will also develop CAR‑T cells from donor/HSCT sources and create banked (off‑the‑shelf) products so patients can receive treatment more quickly. Clinical studies will test these approaches to see if they improve how well and how fast patients respond.
Who could benefit from this research
Good fit: People with relapsed or refractory T‑cell lymphoma who meet the trial's medical and safety criteria would be the intended candidates.
Not a fit: Patients with cancers other than T‑cell lymphoma, or those who do not meet safety or organ‑function requirements for cell therapy, are unlikely to benefit from this work.
Why it matters
Potential benefit: If successful, this could provide people with relapsed T‑cell lymphoma a more effective CAR‑T option that can be delivered faster and to more patients through banked products.
How similar studies have performed: Earlier Phase I work with autologous CD5 CAR‑T showed promising responses (about 44%), but off‑the‑shelf and manufacturing‑improvement approaches are newer and less proven.
Where this research is happening
HOUSTON, UNITED STATES
- BAYLOR COLLEGE OF MEDICINE — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BRENNER, MALCOLM K. — BAYLOR COLLEGE OF MEDICINE
- Study coordinator: BRENNER, MALCOLM K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.